Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.
Peter J GoebellRutika RainaStephanie ChenSanika RegeRuchitbhai M ShahJamie Partridge GrossmanA Reginald WaldeckPublished in: Future oncology (London, England) (2024)
Aim: To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians and evaluate treatment trends and baseline concordance versus guidelines internationally. Materials & methods: Retrospective, cross-sectional data from the Ipsos Global Oncology Monitor database 2018-2020 were used for descriptive analysis of mHSPC patients, treating physicians and treatment utilization. Results: Among the 6198 mHSPC patients from five countries, the most common treatment was either androgen deprivation therapy (ADT) monotherapy or first-generation androgen receptor inhibitor + ADT. Second-generation androgen receptor inhibitor use was only initiating but increasing over the study period. Conclusion: Despite contemporaneous guidelines recommending treatment intensification of ADT in combination with novel antihormonals or docetaxel, 76.1% of reported mHSPC patients received non-guideline-concordant care.
Keyphrases
- prostate cancer
- end stage renal disease
- cross sectional
- ejection fraction
- newly diagnosed
- primary care
- small cell lung cancer
- chronic kidney disease
- healthcare
- stem cells
- clinical trial
- machine learning
- mesenchymal stem cells
- clinical practice
- rectal cancer
- quality improvement
- big data
- study protocol
- cell therapy
- drug induced